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Abstract
Background: Survival from cancer is worse in England than in some European countries. To improve survival,
strategies in England have focused on early presentation (reducing delay to improve stage at diagnosis), improving
quality of care and ensuring equity throughout the patient pathway. We assessed whether primary care
characteristics were associated with later stage cancer at diagnosis (stages 3/4 versus 1/2) for female breast, lung,
colorectal and prostate cancer.
Methods: Data obtained from the National Cancer Registration Service, Quality Outcomes Framework, GP
survey and GP workforce census, linked by practice code. Risk differences (RD) were calculated by primary care
characteristics using a generalised linear model, accounting for patient clustering within practices. Models were
adjusted for age, sex and an area-based deprivation measure.
Results: For female breast cancer, being with a practice with a higher two week wait (TWW) referral rate (RD −1.8 %
(95 % CI −0.5 % to −3.2 %) p = 0.003) and a higher TWW detection rate (RD −1.7 % (95 % CI −0.3 % to −3.0 %)
p = 0.003) was associated with a lower proportion diagnosed later. Being at a practice where people thought it less
easy to book at appointment was associated with a higher percentage diagnosed later (RD 1.8 % (95 % CI 0.2 %
to 3.4 %) p = 0.03). For lung cancer, being at practices with higher TWW referral rates was associated with lower
proportion advanced (RD-3.6 % (95 % CI −1.8 %, −5.5 %) p < 0.001) whereas being at practices with more patients
per GP was associated with higher proportion advanced (RD1.8 % (95 % CI 0.2, 3.4) p = 0.01). A higher rate of
gastrointestinal investigations was associated with a lower proportion of later stage colorectal cancers (RD −2.0 %
(95 % CI −0.6 % to −3.6 %) p = 0.01). No organisational characteristics were associated with prostate cancer stage.
Conclusion: Easier access to primary care, faster referral and more investigation for gastrointestinal symptoms could
reduce the proportion of people diagnosed later for female breast, lung and colorectal, but not prostate cancer.
Differences between the four main cancers suggest different policies may be required for individual cancers to
improve outcomes.
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Background
Survival from cancer varies across European countries
[1, 2]. Stage at diagnosis is strongly related to cancer
mortality and more advanced stage at diagnosis may be
associated with delay in diagnosis [3]. In England, The
National Awareness and Early Diagnosis Initiative
(NAEDI) was announced as part of the 2007 Cancer
Strategy to understand and tackle reasons for more ad-
vanced stage at diagnosis in England compared to other
EU countries [4]. To improve survival, strategies have
focused on early presentation (reducing delay to im-
prove stage at diagnosis), improving quality of care and
ensuring equity throughout the patient pathway. Delays
in diagnosis can be caused by delays in presentation,
primary care delay (first presentation to referral), system
delays (time to investigation) and secondary care delays
(first seen in secondary care to diagnosis) [5, 6].
There has been little research investigating whether
there is an association between characteristics and systems
of primary care and stage of cancer at diagnosis. Research
from Denmark showed associations between some pri-
mary care characteristics and patient or system delay [7].
The authors showed that patients attending a female doc-
tor more often experienced short patient delay but longer
system delay compared to patients attending a male doc-
tor. Patients attending a practice with many services or
seeing a doctor with little former knowledge of the patient
more often experience short system delay. One recent
study [8] found that higher total quality outcome frame-
work (QOF) score protected against unplanned first-time
admissions for cancer, but having no doctors with a UK
primary medical qualification and being less able to offer
appointments within 48 hrs were associated with in-
creased odds of an unplanned first-time admission. Elliss-
Brookes et al. [9] showed patients presenting via the
emergency route have substantially lower 1-year relative
survival than those presenting via other routes. Together,
these studies indicate that primary care characteristics and
systems could have an impact on cancer outcomes.
We investigated whether organisational characteristics
of primary care practices in England were associated
with stage at diagnosis of the four most common can-
cers (female breast, prostate, colorectal and lung cancer).
Methods
Data sources
Stage of cancer at diagnosis, patient-level demographic fac-
tors and primary care characteristics were obtained from a
number of data sources.
Data linkage
We were able to link across a numner of different data-
sets by using the unique GP code [10], where available
and valid thereby providing us information on cancer
characteristics, general practice level features and patient
perceptions about their practice. This process and losses
of data for a variety of different reasons including exclu-
sions is shown in a flow diagram (Fig. 1)
National Cancer Registration Service (NCRS) [11].
There are eight offices of the NCRS in England which
submit a standard dataset of information. Stage data was
more than 70 % complete across England for female
breast (ICD-10 C50), colorectal (ICD-10 C18 to C20),
lung (ICD-10 C33 to C39, and C45) and prostate cancer
(ICD-10 C61) [12]. We included stage data from all rele-
vant fields within NCRS. (For a description of how stage
data are collected within the NCRS see appendix 1 on-
line). Data on patient age, sex, ethnicity and area-based
deprivation (income-based domain of the index of mul-
tiple deprivation (IMD)) quintile were from NCRS data-
set. NCRS information was provided by Public Health
England’s National Cancer Registration Service; data
from the cancer registry is publicly available but only
once it has been aggregated to a level that is not patient-
identifiable.
National Cancer Intelligence Network (NCIN) Practice
Profiles [13]. These bring together data relevant to cancer
in primary care from a range of sources. They were devel-
oped to provide information on general practice (GP) vari-
ation and understand cancer burden. Exposure variables
from this data source were; two week wait (TWW) refer-
ral rate (number of TWW referrals for any cancer per
100,000 population), TWW conversion rate (percentage of
all TWW referrals with cancer), TWW detection rate
(percentage of new cancers treated which were referred
through TWW system), average colonoscopy, sigmoidos-
copy and endoscopy rate (average colonoscopy, sigmoid-
oscopy and upper gastrointestinal endoscopy in-patient or
day case procedures, rate per 100,000), emergency admis-
sions (number of persons admitted to hospital as an in-
patient or day-case via an emergency admission, with a
diagnostic code that includes cancer, per 100,000 popula-
tion) and GP deprivation (income-based domain of IMD).
Most data is freely available, however some small numbers
within the profiles are only accessible through specific
routes. A version of the GP Practice Profiles with poten-
tially identifiable data suppressed is publicly available via
the Public Health England National Cancer Intelligence
Network’s Cancer Commissioning Toolkit.
The Quality and Outcomes Framework (QOF) is a finan-
cial incentive scheme that rewards GPs depending on
their achievement against quality indicators [14]. The total
QOF score was used with higher scores indicating better
performance. The four domains within QOF (clinical,
organisational, additional services and patient experience)
were not used as separate variables as they were strongly
correlated with each other and the total QOF score.
The individual cancer indicator score was also strongly
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Fig. 1 Data flow due to data linkage, missing data and exclusions from dataset
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correlated with the total QOF score. Information on list
size (number of patients per practice) was used with infor-
mation on the number of general practitioners per prac-
tice (from the GP workforce census, see below) to
calculate the average number of patients per general prac-
titioner at each practice. QOF data is freely available, re-
used with the permission of the Health and Social Care
Information Centre.
The General Practice Patient Survey is a questionnaire
sent to a random sample of adults registered at GPs
across England [15]. It gives patients an opportunity to
comment on their experience of their GP. Exposure
variables from this data were; percentage of patients
responding ‘yes’ to the question ‘Were you able to get an
appointment see or speak to someone?’ 2011/12 and
percentage of patients responding ‘always’, ‘almost always’
or ‘a lot of the time’ to the question ‘Were you able to
see your preferred doctor?’ 2010/11. These aspects were
chosen because studies have shown easier access (ability
to get an appointment) and greater continuity (ability to
see a preferred doctor) can be associated with reduced
hospital admissions [16, 17]. In 2011/12, 2.74 million
questionnaires were sent with a response rate of 38 %
(5.56 million sent in 2010/11 with 36 % response rate).
Data is freely available, re-used with the permission of
the Health and Social Care Information Centre.
General Practice workforce census is collected annually
and includes information on the numbers of general
practitioners working in primary care [18]. Exposure
variables from this data source were: age, gender and
country of primary medical qualification of general prac-
titioners, and the number of general practitioners per
practice (full time equivalent). Single handed practice
was not included as a separate exposure variable because
there were only a small number (890, 11 %) of single
handed practices. Data is freely available, re-used with
the permission of the Health and Social Care Informa-
tion Centre.
Health & Social Care Information Centre (HSCIC) In-
dicator Portal brings together health and social care in-
dicators [19]. The rurality of GPs (based on population
density of the GP postcode) was obtained from this
source. Data is freely available, re-used with the permis-
sion of the Health and Social Care Information Centre.
(For more details and how we operationalised the ex-
posure variables see the Additiona file 1: Table S’a’).
Inclusion/exclusion criteria
We included all practices that were in the NCIN Practice
Profiles [13]. These were practices in the 2011/12 QOF
data with the following exclusions; practices with a patient
list size less than 1000, a greater than 10 % difference in
list size between 2011/12 QOF and Attribution Dataset
April 2010, practice was missing in Attribution Dataset
April 2010 or the practice could not be allocated to a
CCG. This resulted in 7,965 practices (158 of 8,123 prac-
tices within QOF 2011/12 were excluded).
Statistical methods
Our primary outcome was the proportion of patients who
were diagnosed with advanced cancer compared to those
with an earlier stage. Our null hypothesis was that charac-
teristics and systems of primary care would not influence
the proportion with advanced versus earlier stage for each
of our four specific cancer sites after accounting for
patient-level demographic factors. We defined advanced
stage as stages 3 or 4 (regional or metastatic) compared to
stages 1 or 2 (locally confined) using data from the TNM
classification (see appendix 1 for further description of
staging).
We derived two sets of exposure variables (a) patient
level (age, sex, ethnicity and area deprivation) and (b)
primary care level. The latter were divided into four do-
mains (i) GP demographics (ii) GP general performance
(iii) GP specific cancer activities (iv) GP other activities.
We decided that we would use a risk difference rather
than a risk ratio as the most appropriate effect estimate
as this enables one to easily calculate the impact of a GP
characteristic in absolute terms. We therefore used a
generalised linear model for the binomial family with an
identity link function. Our outcome variable, stage of
cancer at diagnosis, was coded as zero for early stage
(stages 1 or 2) and one for late stage (stages 3 or 4). We
allowed errors in the model to be correlated within each
GP practice to account for clustering of patients within
GPs, thereby producing more conservative confidence
inetrvals and p-values. Negative risk differences show
that patients are less likely to be diagnosed at an ad-
vanced stage (3 or 4) compared to patients in the base-
line group. The opposite is true for positive differences.
Risk differences are presented as percentage risk differ-
ence. Analyses were conducted using STATA 13.
Female breast cancer and prostate cancer models were
adjusted for age at diagnosis and patient level income-
based deprivation. Colorectal and lung cancer models
were adjusted for age at diagnosis, sex and patient level
area-based deprivation. We developed a conceptual
model (Additional file 1: Figure S’a’) on the potential
inter-relationships between the primary care level fac-
tors. We had no a priori knowledge of this causal path-
way and using the conceptual model decided not to
mutually adjust for characteristics or systems of primary
care as they may have been on the causal pathway and
hence the coefficients from such a model would be mis-
leading due to over-adjustment.
We undertook a series of sensitivity analyses to assess
the impact of missing ethnicity data and of using stage
data from different fields within NCRS. Missing data for
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stage of cancer at diagnosis was analysed to investigate
whether there were systematic reasons for data being
missing (missing not at random). Multiple imputation
was used to generate missing values for stage for each of
the four main cancers separately. The ice program was
used to perform imputation in Stata 13. Imputation was
performed on stage with sex, deprivation quintile and
age included in the imputation model. A further model
using the significant exposure variables for each cancer
(female breast cancer included rurality, two week wait
(TWW) referral rate, TWW detection rate, emergency
admission rate, gender of general practitioners and ease
of booking an appointment; prostate cancer included GP
practice deprivation and practices rate of colonoscopy,
sigmoidoscopy and endoscopy; colorectal cancer in-
cluded practices rate of colonoscopy, sigmoidoscopy and
endoscopy; lung cancer included TWW referral rate,
TWW conversion rate, age and gender of general practi-
tioners, number of patients per GP and emergency ad-
mission rates ). Twenty imputed data sets were created
for each model.
Results
There were 363,991 tumours diagnosed in 2012 (all can-
cers excluding non-melanoma skin cancers, ICD-10 C00
to C97 excluding C44). Of these there were 42,572 fe-
male breast cancers, 36,822 prostate cancers, 34,458
colorectal cancer and 38,652 lung cancers, accounting
for 42 % of all cancers diagnosed in 2012. From these
34,119 female breast cancers (5,666 stage 3 or 4, 16.6 %),
27,880 prostate cancers (10,756 stage 3 or 4, 38.6 %),
27,079 colorectal cancers (14,793 stage 3 or 4, 54.6 %)
and 28,479 lung cancers (21,520 stage 3 or 4, 75.6 %)
were included in the analyses (see Fig. 1 for details of in-
clusion/exclusion of tumours). These were from patients
at 7,786 GP practices across England.
(For details of the number of tumours of each cancer
type by patient and GP variable see the Additional file 1:
Table Sb).
At an individual level we found that various exposures
could be important confounders for presenting with ad-
vanced female breast cancer (see Table 1). Non-white vs.
white women and women living in more deprived areas
were more likely to be diagnosed at a more advanced stage
(RD 6.0 % (95 % CI 3.3 % to 8.6 %) p < 0.001; Q5 vs. Q1 RD
3.9 % (95 % CI 2.5 % to 5.3 %), p-value for trend <0.001).
Women aged 15–44 years were more likely to be diag-
nosed at a more advanced stage than women aged 65 years
and over whereas women aged 45–64 years were less likely
to be diagnosed at a more advanced stage (15-44years vs. 65
+ RD 2.1 % (95 % CI 0.6 % to 3.6 %) p = 0.01; 45–64 years
vs. 65+ RD −3.2 % (95 % CI −4.1 % to −2.4 %) p < 0.001).
A variety of GP exposures were associated with stage at
presentation but after adjustment for age and deprivation
the following predicted lower proportion with advanced
stage female breast cancer: having a GP in a town/fringe
area compared to urban area (RD −1.5 % (95 % CI −2.5 %
to −0.4 %) p = 0.01), ), practices with higher two week wait
(TWW) referral rate and a higher TWW detection rate
(Q5 vs. Q1 RD −1.5 % (95 % CI −2.8 % to −0.2 %) p value
for trend = 0.01; Q5 vs. Q1 RD −1.3 % (95 % CI −2.6 % to
0.0 %) p value for trend = 0.01) and practices that had a
higher emergency admission rate (Q5 vs. Q1 RD −2.0 %
(95 % CI −3.3 % to −0.8 %) p value for trend = 0.03). In
contrast having only female general practitioners at the
practice and being at a practice where people thought it
was less easy to book an appointment was associated with
a higher percentage diagnosed at a more advanced stage
(all female GPs: RD 4.0 % (95 % CI 0.6 % to 7.4 %) p =
0.02; <80 % thought easy to book appointment compared
to >90 % RD 1.7 % (95 % CI 0.1 % to 3.3 %) p = 0.04.
At the individual level we found that various exposures
could be important confounders for presenting with ad-
vanced prostate cancer (see table 1). Men living in more
deprived areas were more likely to be diagnosed at a
more advanced stage than those living in less deprived
areas (Q5 vs. Q1 RD 4.7 % (95 % CI 2.7 % to 6.8 %), p-
value for trend <0.001). Non-white vs. white men and
younger men were less likely to be diagnosed at a more
advanced stage (RD −6.0 % (95 % CI −10.3 % to −1.7 %)
p = 0.01; 45-64 years vs. 65+ RD −8.1 % (95 % CI −9.4 %
to −6.8 %) p < 0.001, 15-44 years vs. 65+ RD −19.0 %
(95 % CI −29.5 % to −8.5 %) p < 0.001).
After adjustment for age and deprivation GP practice
deprivation and practices with higher rates of colonos-
copy, sigmoidoscopy and endoscopy were associated
with a higher percentage diagnosed at a more advanced
stage (Q5 vs. Q1 RD 1.8 % (95 % CI −0.6 % to 4.2 %) p-
value for trend 0.04; tertile 3 vs. tertile 1 RD 2.4 % (95 %
CI 0.9 % to 3.9 %) p value for trend = 0.002).
For colorectal cancer, at the individual level, we found
that various exposures could be important confounders
for presenting later (see Table 2). Non-white vs. white
people and younger people were more likely to be diag-
nosed at a more advanced stage (RD 6.7 % (95 % CI
2.7 % to 10.7 %) p = 0.001; 15-44 years vs. 65+ RD
10.3 % (95 % CI 7.1 % to 13.4 %) p < 0.001, 45-64 years
vs. 65+ RD 6.0 % (95 % CI 4.6 % to 7.3 %) p < 0.001).
After adjustment for age, sex and deprivation the only
GP exposure which was associated with stage at presen-
tation was the average colonoscopy, sigmoidoscopy and
endoscopy rate. We found that a higher average colon-
oscopy, sigmoidoscopy and endoscopy rate was associ-
ated with a lower percentage of people diagnosed at a
more advanced stage (tertile 3 vs. tertile 1 RD −2.0 %
(95%CI −3.5 % to −0.5 %) p value for trend = 0.01).
Age and gender were important confounders for pre-
senting with advanced lung cancer (see Table 2). Women
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Table 1 Univariate and adjusted risk differences for female breast cancer and prostate cancer
Female breast cancer Prostate cancer









65 + yrs Baseline Baseline Baseline Baseline
45-64 years −3.2 (−4.1 to −2.4) <0.001 −3.2 (−4.1 to −2.4) <0.001 −8.1 (−9.4 to −6.8) <0.001 −8.2 (−9.4 to −6.9) <0.001
15-44 years 2.1 (0.6 to 3.6) 0.01 1.9 (0.4 to 3.4) 0.01 −19.0 (−29.5 to −8.5) <0.001 −19.7 (−30.2 to −9.3) <0.001
Ethnicity
White Baseline Baseline
Non-white 6.0 (3.3 to 8.6) <0.001 −6.0 (−10.3 to −1.7) 0.01
Deprivation
Q1 (least deprived) Baseline Baseline Baseline Baseline
Q2 −0.6 (−1.8 to 0.6) −0.8 (−1.9 to 0.4) 2.1 (0.5 to 3.8) 2.0 (0.4 to 3.7)
Q3 0.0 (−1.2 to 1.2) −0.1 (−1.3 to 1.0) 2.7 (1.0 to 4.5) 2.6 (0.9 to 4.3)
Q4 2.5 (1.2 to 3.8) 2.2 (1.0 to 3.5) 4.1 (2.2 to 6.0) 4.2 (2.3 to 6.0)
Q5 (most deprived) 3.9 (2.5 to 5.3) <0.001 3.6 (2.2 to 5.0) <0.001 4.7 (2.7 to 6.8) <0.001 4.9 (2.9 to 7.0) <0.001
GP demographics Number of patients per GP
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −0.1 (−1.5 to 1.3) −0.1 (−1.4 to 1.3) −1.2 (−3.1 to 0.8) −1.1 (−3.0 to 0.9)
Q3 −0.8 (−2.1 to 0.6) −0.8 (−2.1 to 0.6) −0.9 (−2.9 to 1.1) −0.7 (−2.7 to 1.3)
Q4 0.3 (−1.1 to 1.7) 0.1 (−1.3 to 1.5) −0.8 (−2.7 to 1.2) −0.8 (−2.8 to 1.1)
Q5 (highest) −0.1 (−1.5 to 1.2) 0.94 −0.6 (−1.9 to 0.7) 0.48 −2.3 (−4.2 to −0.4) 0.05 −2.3 (−4.2 to −0.4) 0.04
Training practice
No Baseline Baseline Baseline Baseline
Yes 0.9 (0.1 to 1.8) 0.03 0.6 (−0.2 to 1.5) 0.16 −0.8 (−2.0 to 0.5) 0.23 −0.9 (−2.1 to 0.4) 0.18
GPs aged 50 and over
Some Baseline Baseline Baseline Baseline
None 0.6 (−1.0 to 2.1) 0.46 0.3 (−1.2 to 1.8) 0.66 −0.5 (−2.7 to 1.8) 0.70 −0.5 (−2.8 to 1.7) 0.64
All 1.5 (−0.4 to 3.3) 0.13 0.8 (−1.0 to 2.6) 0.41 −2.1 (−4.5 to 0.4) 0.10 −2.5 (−5.0 to −0.1) 0.04
GPs female
Some Baseline Baseline Baseline Baseline
None −0.1 (−1.7 to 1.6) 0.95 −0.7 (−2.3 to 0.9) 0.40 −0.5 (−2.7 to 1.7) 0.68 −1.0 (−3.1 to 1.2) 0.38












Table 1 Univariate and adjusted risk differences for female breast cancer and prostate cancer (Continued)
GPs qualified in UK
Some Baseline Baseline Baseline Baseline
None 1.5 (−0.4 to 3.4) 0.13 0.4 (−1.4 to 2.2) 0.68 −2.2 (−4.8 to 0.3) 0.08 −2.5 (−5.0 to 0.0) 0.05
All −0.4 (−1.3 to 0.5) 0.40 −0.3 (−1.1 to 0.6) 0.55 0.9 (−0.5 to 2.2) 0.20 1.1 (−0.2 to 2.4) 0.09
GP level deprivation
Q1 (least deprived) Baseline Baseline Baseline Baseline
Q2 0.4 (−0.9 to 1.7) 0.3 (−1.0 to 1.5) 1.9 (0.1 to 3.7) 1.0 (−0.9 to 2.8)
Q3 0.1 (−1.2 to 1.4) −0.6 (−1.9 to 0.7) 3.2 (1.3 to 5.0) 2.1 (0.2 to 4.0)
Q4 1.2 (−0.2 to 2.5) −0.2 (−1.6 to 1.2) 3.5 (1.6 to 5.3) 2.1 (0.1 to 4.2)
Q5 (most deprived) 4.4 (2.9 to 5.9) <0.001 2.5 (0.8 to 4.2) 0.14 3.5 (1.5 to 5.6) <0.001 1.8 (−0.6 to 4.2) 0.04
GP rurality
Urban > 10 K Baseline Baseline Baseline Baseline
Town and fringe −2.4 (−3.5 to −1.4) <0.001 −1.5 (−2.5 to −0.4) 0.01 −2.0 (−3.7 to −0.4) 0.01 −1.6 (−3.3 to 0.0) 0.05
Village, hamlet & isolated dwellings −2.5 (−4.7 to −0.4) 0.02 −1.6 (−3.7 to 0.4) 0.12 −2.0 (−5.1 to 1.0) 0.19 −1.2 (−4.3 to 1.9) 0.44
GP general
performance
Able to book appointment
90 % and over Baseline Baseline Baseline Baseline
80-90 % 1.0 (0.1 to 1.9) 0.6 (−0.3 to 1.4) 0.9 (−0.4 to 2.2) 0.8 (−0.5 to 2.1)
<80 % 3.1 (1.5 to 4.7) <0.001 1.7 (0.1 to 3.3) 0.04 −1.3 (−3.6 to 1.1) 0.92 −2.0 (−4.3 to 0.4) 0.70
Able to see preferred GP
80 % and over Baseline Baseline Baseline Baseline
60-80 % 0.7 (−0.3 to 1.7) 0.4 (−0.6 to 1.4) 0.2 (−1.2 to 1.7) 0.2 (−1.2 to 1.6)
<60 % 1.7 (0.5 to 2.9) 0.01 1.0 (−0.2 to 2.2) 0.10 −0.7 (−2.5 to 1.0) 0.47 −0.9 (−2.7 to 0.9) 0.35
Total QOF points
990 to 1000 (max) points Baseline Baseline Baseline Baseline
980 to 989 points −0.2 (−1.3 to 0.9) −0.4 (−1.4 to 0.7) 1.4 (−0.3 to 3.1) 1.3 (−0.4 to 2.9)
960 to 979 points 1.2 (0.0 to 2.4) 0.9 (−0.3 to 2.1) 1.2 (−0.5 to 2.8) 1.1 (−0.5 to 2.8)
<960 points 1.4 (0.0 to 2.7) 0.02 0.9 (−0.4 to 2.2) 0.11 0.7 (−1.3 to 2.6) 0.23 0.4 (−1.5 to 2.3) 0.75
GP specific
cancer activities
Two week wait referral rate
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −1.8 (−3.2 to −0.5) −1.3 (−2.6 to 0.1) 0.1 (−1.8 to 1.9) 0.1 (−1.8 to 2.0)
Q3 −0.7 (−2.1 to 0.7) −0.1 (−1.4 to 1.2) 1.6 (−0.3 to 3.6) 1.8 (−0.1 to 3.8)
Q4 −2.9 (−4.2 to −1.6) −2.0 (−3.3 to −0.7) 1.4 (−0.5 to 3.4) 1.2 (−0.7 to 3.2)












Table 1 Univariate and adjusted risk differences for female breast cancer and prostate cancer (Continued)
Two week wait conversion
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −1.0 (−2.4 to 0.3) −0.7 (−2.0 to 0.7) 2.1 (0.1 to 4.1) 2.0 (0.0 to 4.0)
Q3 −1.7 (−3.1 to −0.4) −1.3 (−2.6 to 0.0) 1.1 (−0.9 to 3.1) 0.9 (−1.1 to 2.9)
Q4 −1.3 (−2.6 to 0.0) −1.0 (−2.3 to 0.3) 0.9 (−1.1 to 2.9) 0.7 (−1.3 to 2.7)
Q5 (highest) −1.0 (−2.4 to 0.3) 0.12 −0.7 (−2.0 to 0.6) 0.23 1.6 (−0.3 to 3.5) 0.34 1.4 (−0.5 to 3.3) 0.46
Two week wait detection
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −0.5 (−1.9 to 0.8) −0.2 (−1.6 to 1.1) 0.5 (−1.4 to 2.4) 0.5 (−1.5 to 2.4)
Q3 −1.6 (−2.9 to −0.2) −1.1 (−2.4 to 0.2) 1.9 (0.0 to 3.8) 1.9 (0.0 to 3.8)
Q4 −2.6 (−4.1 to −1.2) −1.9 (−3.3 to −0.6) 2.8 (0.7 to 4.8) 2.7 (0.7 to 4.8)
Q5 (highest) −2.0 (−3.4 to −0.6) <0.001 −1.3 (−2.6 to 0.0) 0.01 0.3 (−1.7 to 2.2) 0.26 0.6 (−1.3 to 2.5) 0.15
GP other activities Average colonoscopy, sigmoidoscopy
and upper GI endoscopy
T1 (lowest) Baseline Baseline Baseline Baseline
T2 −0.8 (−1.9 to 0.2) −0.6 (−1.6 to 0.4) 2.3 (0.8 to 3.8) 2.4 (0.9 to 3.9)
T3 (highest) 0.5 (−0.5 to 1.6) 0.33 0.6 (−0.4 to 1.6) 0.28 2.5 (1.0 to 4.0) 0.001 2.4 (0.9 to 3.9) 0.002
Emergency admissions
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −1.9 (−3.2 to −0.5) −1.6 (−2.8 to −0.3) 1.2 (−0.7 to 3.2) 1.5 (−0.4 to 3.4)
Q3 −0.3 (−1.7 to 1.0) −0.1 (−1.5 to 1.2) 1.7 (−0.2 to 3.6) 1.7 (−0.2 to 3.6)
Q4 −1.0 (−2.3 to 0.3) −0.8 (−2.1 to 0.5) 1.7 (−0.3 to 3.6) 1.4 (−0.6 to 3.3)












Table 2 Univariate and adjusted risk differences for colorectal cancer and lung cancer
Colorectal cancer Lung cancer











65 + yrs Baseline Baseline Baseline Baseline
45-64 years 6.0 (4.6 to 7.3) <0.001 5.9 (4.6 to 7.3) <0.001 3.1 (1.7 to 4.5) <0.001 3.3 (1.9 to 4.6) <0.001
15-44 years 10.3 (7.1 to 13.4) <0.001 10.1 (6.9 to 13.3) <0.001 4.2 (−1.5 to 9.9) 0.15 4.5 (−1.2 to 10.2) 0.12
Sex
Male Baseline Baseline Baseline Baseline
Female 0.1 (−1.1 to 1.4) 0.82 0.0 (−1.2 to 1.2) 1.00 −3.1 (−4.1 to −2.1) <0.001 −3.3 (−4.3 to −2.3) <0.001
Ethnicity
White Baseline Baseline
Non-white 6.7 (2.7 to 10.7) 0.001 −0.7 (−4.6 to 3.1) 0.71
Deprivation
Q1 (least deprived) Baseline Baseline Baseline Baseline
Q2 −0.4 (−2.2 to 1.4) −0.3 (−2.1 to 1.5) −0.5 (−2.2 to 1.3) −0.4 (−2.2 to 1.4)
Q3 −0.3 (−2.2 to 1.5) −0.3 (−2.1 to 1.6) 0.3 (−1.4 to 2.1) 0.4 (−1.3 to 2.1)
Q4 1.0 (−0.9 to 2.9) 0.9 (−1.0 to 2.8) −0.3 (−2.0 to 1.4) −0.4 (−2.1 to 1.3)
Q5 (most deprived) 1.5 (−0.6 to 3.5) 0.07 1.1 (−0.9 to 3.1) 0.14 −1.0 (−2.7 to 0.7) 0.29 −1.3 (−3.0 to 0.4) 0.13
GP demographics Number of patients per GP
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 1.0 (−0.9 to 2.9) 1.1 (−0.8 to 3.0) 0.5 (−1.1 to 2.2) 0.6 (−1.0 to 2.2)
Q3 1.1 (−0.9 to 3.1) 1.1 (−0.9 to 3.1) 0.6 (−1.0 to 2.3) 0.7 (−0.9 to 2.3)
Q4 1.6 (−0.3 to 3.6) 1.5 (−0.4 to 3.4) 1.7 (0.1 to 3.3) 1.7 (0.2 to 3.3)
Q5 (highest) 0.4 (−1.6 to 2.4) 0.54 0.2 (−1.8 to 2.1) 0.74 2.0 (0.4 to 3.5) 0.01 1.8 (0.2 to 3.4) 0.01
Training practice
No Baseline Baseline Baseline Baseline
Yes 0.2 (−1.0 to 1.5) 0.71 0.0 (−1.2 to 1.3) 0.95 0.6 (−0.5 to 1.6) 0.27 0.6 (−0.5 to 1.6) 0.28
GPs aged 50 and over
Some Baseline Baseline Baseline Baseline
None −1.2 (−3.5 to 1.1) 0.30 −1.4 (−3.6 to 0.9) 0.24 −2.6 (−4.3 to −0.8) 0.01 −2.5 (−4.3 to −0.7) 0.01













Table 2 Univariate and adjusted risk differences for colorectal cancer and lung cancer (Continued)
Some Baseline Baseline Baseline Baseline
None −0.4 (−2.7 to 1.9) 0.73 −0.8 (−3.1 to 1.6) 0.53 1.3 (−0.5 to 3.1) 0.17 1.3 (−0.5 to 3.1) 0.14
All −3.0 (−8.2 to 2.2) 0.27 −3.5 (−8.7 to 1.7) 0.19 −4.5 (−8.4 to −0.6) 0.03 −4.6 (−8.4 to −0.7) 0.02
GPs qualified in UK
Some Baseline Baseline Baseline Baseline
None −0.1 (−2.7 to 2.6) 0.95 −0.5 (−3.2 to 2.2) 0.71 −0.6 (−2.6 to 1.5) 0.59 −0.5 (−2.6 to 1.5) 0.61
All −0.6 (−2.0 to 0.7) 0.35 −0.4 (−1.8 to 0.9) 0.51 −0.2 (−1.3 to 0.9) 0.68 −0.3 (−1.4 to 0.8) 0.61
GP level deprivation
Q1 (least deprived) Baseline Baseline Baseline Baseline
Q2 −1.2 (−3.1 to 0.7) −1.4 (−3.3 to 0.6) −1.8 (−3.5 to −0.1) −1.8 (−3.5 to −0.1)
Q3 −1.0 (−2.9 to 0.8) −1.3 (−3.3 to 0.7) −0.3 (−2.0 to 1.4) −0.6 (−2.3 to 1.2)
Q4 0.5 (−1.4 to 2.5) −0.2 (−2.4 to 1.9) −0.9 (−2.5 to 0.8) −1.2 (−3.0 to 0.7)
Q5 (most deprived) 0.9 (−1.2 to 3.0) 0.17 −0.4 (−2.9 to 2.1) 1.00 −2.6 (−4.3 to −0.9) 0.03 −2.8 (−4.8 to −0.8) 0.04
GP rurality
Urban > 10 K Baseline Baseline Baseline Baseline
Town and fringe −0.7 (−2.5 to 1.0) 0.40 −0.1 (−1.9 to 1.6) 0.87 0.0 (−1.5 to 1.5) 0.96 −0.2 (−1.7 to 1.4) 0.83
Village, hamlet & isolated dwellings −0.3 (−3.5 to 2.8) 0.84 0.2 (−2.9 to 3.3) 0.90 0.7 (−2.5 to 3.9) 0.67 0.4 (−2.9 to 3.6) 0.82
GP general
performance
Able to book appointment
90 % and over Baseline Baseline Baseline Baseline
80-90 % 0.1 (−1.2 to 1.4) −0.1 (−1.4 to 1.2) −0.7 (−1.7 to 0.4) −0.5 (−1.6 to 0.6)
<80 % 1.1 (−1.3 to 3.5) 0.46 0.3 (−2.1 to 2.7) 0.95 −0.5 (−2.4 to 1.4) 0.32 −0.3 (−2.2 to 1.7) 0.52
Able to see preferred GP
80 % and over Baseline Baseline Baseline Baseline
60-80 % −0.6 (−2.0 to 0.9) −0.6 (−2.1 to 0.8) −1.4 (−2.6 to −0.2) −1.3 (−2.5 to 0.0)
<60 % 0.5 (−1.3 to 2.3) 0.65 0.1 (−1.7 to 1.9) 0.96 −1.4 (−2.8 to 0.0) 0.05 −1.2 (−2.6 to 0.2) 0.09
Total QOF points
990 to 1000 (max) points Baseline Baseline Baseline Baseline
980 to 989 points 0.1 (−1.4 to 1.7) 0.0 (−1.6 to 1.5) −0.8 (−2.1 to 0.5) −0.7 (−2.0 to 0.6)
960 to 979 points 0.6 (−1.2 to 2.4) 0.4 (−1.4 to 2.2) −0.4 (−1.8 to 1.0) −0.5 (−1.9 to 0.9)
<960 points −0.5 (−2.5 to 1.4) 0.93 −0.9 (−2.8 to 1.1) 0.53 −0.8 (−2.4 to 0.8) 0.29 −0.7 (−2.3 to 0.9) 0.65
GP specific cancer
activities
Two week wait referral rate
Q1 (lowest) Baseline Baseline Baseline Baseline
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Q3 −0.6 (−2.5 to 1.3) −0.3 (−2.2 to 1.7) −2.3 (−3.8 to −0.7) −2.3 (−3.9 to −0.8)
Q4 −0.7 (−2.6 to 1.3) −0.2 (−2.1 to 1.8) −2.1 (−3.7 to −0.5) −2.0 (−3.6 to −0.5)
Q5 (highest) −1.2 (−3.1 to 0.8) 0.13 −0.6 (−2.6 to 1.4) 0.39 −3.4 (−5.0 to −1.8) <0.001 −3.3 (−4.9 to −1.7) <0.001
Two week wait conversion
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 0.8 (−1.2 to 2.7) 1.0 (−1.0 to 3.0) 1.3 (−0.3 to 3.0) 1.5 (−0.1 to 3.1)
Q3 −2.5 (−4.5 to −0.5) −2.0 (−4.0 to −0.1) 1.2 (−0.4 to 2.9) 1.3 (−0.4 to 2.9)
Q4 −1.8 (−3.7 to 0.2) −1.3 (−3.2 to 0.7) 3.6 (2.0 to 5.2) 3.6 (2.0 to 5.2)
Q5 (highest) 0.6 (−1.3 to 2.6) 0.56 1.2 (−0.7 to 3.1) 0.96 4.1 (2.5 to 5.7) <0.001 4.0 (2.4 to 5.6) <0.001
Two week wait detection
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 1.5 (−0.5 to 3.4) 1.7 (−0.2 to 3.7) −1.1 (−2.7 to 0.5) −1.1 (−2.6 to 0.5)
Q3 0.7 (−1.2 to 2.6) 0.9 (−0.9 to 2.8) −1.0 (−2.5 to 0.6) −0.8 (−2.4 to 0.7)
Q4 −1.2 (−3.3 to 0.9) −0.8 (−2.9 to 1.2) −0.7 (−2.3 to 0.9) −0.6 (−2.2 to 1.1)
Q5 (highest) 1.3 (−0.6 to 3.3) 0.92 1.6 (−0.4 to 3.5) 0.72 −1.3 (−2.9 to 0.3) 0.22 −1.3 (−2.9 to 0.3) 0.23
GP other activities Average colonoscopy, sigmoidoscopy and
upper GI endoscopy
T1 (lowest) Baseline Baseline Baseline Baseline
T2 −0.3 (−1.8 to 1.2) 0.0 (−1.5 to 1.5) −1.1 (−2.4 to 0.1) −1.1 (−2.3 to 0.2)
T3 (highest) −2.4 (−3.9 to −0.9) 0.002 −2.0 (−3.5 to −0.5) 0.01 −0.7 (−2.0 to 0.5) 0.27 −0.5 (−1.7 to 0.8) 0.48
Emergency admissions
Q1 (lowest) Baseline Baseline Baseline Baseline
Q2 −0.2 (−2.1 to 1.8) 0.2 (−1.8 to 2.1) 0.4 (−1.3 to 2.0) 0.4 (−1.2 to 2.1)
Q3 −0.7 (−2.6 to 1.3) −0.3 (−2.2 to 1.7) 1.0 (−0.6 to 2.7) 1.0 (−0.6 to 2.7)
Q4 −0.7 (−2.7 to 1.3) −0.2 (−2.2 to 1.7) 0.8 (−0.8 to 2.3) 0.9 (−0.7 to 2.5)












were less likely to be diagnosed at a more advanced
stage than men (RD −3.3 % (95 % CI-4.3 % to −2.3 %) p
< 0.001). People aged 45–64 years were more likely to be
diagnosed at a more advanced stage than people aged 65
and over (RD 3.3 % (95 % CI 1.9 % to 4.6 %) p < 0.001)
but there was no difference between people aged 15–44
years and people 65 and over (RD 4.5 % (95 % CI −1.2 %
to 10.2 %) p = 0.12).
After adjustment for age, sex and deprivation, being at
a practice with a higher TWW referral rate, having no
GPs aged 50 and over and having all female GPs was as-
sociated with a lower percentage diagnosed with more
advanced stage lung cancer (Q5 vs. Q1 RD-3.3 % (95 %
CI −4.9 % to −1.7 %) p-value for trend <0.001; none vs.
some RD-2.5 % (95%CI −4.3 % to −0.7 %) p = 0.01; all vs
some. RD-4.6 % (95%CI −8.4 % to −0.7 %) p = 0.02). In
contrast being at a practice which had more patients per
GP, being at a practice with a higher TWW conversion
rate and being at a practice that had a higher emergency
admission rate was associated with a higher percentage
diagnosed at a more advanced stage (Q5 vs. Q1 RD
1.8 % (95 % CI0.2 % to 3.4 %), p-value for trend 0.01; Q5
vs. Q1 RD 4.0 % (2.4 % to 5.5 %) p-value for trend
<0.001; Q5 vs. Q1 RD 1.6 % (95%CI 0.0 % to 3.2 %)
p-value fpr trend 0.04). There is a weak negative correl-
ation between TWW referral and TWW conversion and
this may explain some of the association between higher
TWW conversion and more advanced stage at diagnosis.
Missing stage data and multiple imputation
There was no systematic pattern of missing stage data be-
tween patient age and sex across the four common cancers.
For female breast, prostate and lung cancer people who
were more deprived were less likely to have missing stage
data. Comparison of risk difference with and without the
use of stage imputation shows very small alterations to risk
differences which did not alter trends or interpretation for
exposure variables.
Sensitivity analysis
For cancers with stage data ethnicity was missing for
36.1 % of patients with female breast cancer, 47.9 % of
prostate cancer, 33.1 % of colorectal cancer and 30.7 % of
lung cancer. To assess the impact of adjusting for ethni-
city, results for patients with complete ethnicity data
adjusted for age, sex, deprivation and ethnicity were com-
pared to an analysis excluding ethnicity. There were only
very small changes in risk differences between these ana-
lyses with no change to the trends or conclusions drawn
from the results. This is probably due to the distribution
of ethnicity with 96 % of those with staged female breast,
colorectal, lung and prostate cancer being white.
The main analysis used all relevant stage data from
NCRS (see Additional file 1: appendix 1 for description
of collection of stage data). If only the data from the
NCRS ‘Stage best’ field was used 32,590 (81.0 %) of fe-
male breast cancers had staging data, 26,847 (78.4 %) of
prostate cancers, 25,362 (80.7 %) of colorectal cancer
and 27,134 (82.2 %) of lung cancers. Analysis to assess
the impact of using all relevant stage data compared to
using the ‘Stage Best’ field alone showed very small
changes to the risk differences for female breast, colorectal
and lung cancer. There was no change to the trends or
conclusions of the results. For prostate cancer there were
some slightly greater changes to the risk differences.
Due to the large proportion of lung cancers diagnosed
at stage 3 or 4 we conducted an analysis to compare
stage 4 with stage 1, 2 or 3. The trends for number of
patients per GP, TWW referral rate and TWW conver-
sion rate did not alter. However the relationship between
GP demographics (age and gender) and emergency ad-
missions were attenduated.
Discussion
We have observed that some characteristics and systems
of primary care practices are associated with the stage of
cancer at diagnosis, but these vary by cancer type. If
these associations are causal, then these results have im-
portant policy implications and could reduce cancer
mortality rates for these four cancers.
For female breast cancer being at a practice where
people thought it was easier to get an appointment and
being at a practice more likely to use the TWW referral
system may reduce more advanced stage at diagnosis.
Having only female general practitioners may hinder
diagnosis at an earlier stage. This reflects findings by
Hansen et al. [7] that even though patients of female
doctors had shorter patient delays they more often expe-
rienced longer system delays. These may suggest that ac-
cess to primary care and speed of referral to secondary
care are important in the earlier diagnosis of female
breast cancer.
For prostate cancer the picture is more mixed with indi-
vidual characteristics having a large influence on stage at
diagnosis which may suggest differences are due to under-
lying tumour biology and factors affecting patient delay.
Counter-intuitively, higher rates of colonoscopy, sigmoid-
oscopy and endoscopy were associated with more ad-
vanced stage at diagnosis. It is possible this reflects a
higher prevalence of gastrointestinal symptoms in areas
where less prostate specific antigen (PSA) testing is being
done, some practices focus more on colorectal cancer
than prostate cancer, or this was a type I error.
Being at a practice using more investigations for
gastrointestinal symptoms appeared to reduce more ad-
vanced stage diagnosis of colorectal cancer. This echoes
research which showed that screening sigmoidoscopy and
colonoscopy reduced colorectal cancer mortality [20].
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Younger patients were more likely to present with more
advanced cancers as has been noted previously in the lit-
erature [21].
For lung cancer having fewer patients per general practi-
tioner, being at a practice more likely to use the TWW re-
ferral system and at a practice where a larger proportion
of cancers are diagnosed through TWW may reduce more
advanced stage diagnosis. This could suggest that access
to primary care and speed of referral to secondary care
could be important in the early diagnosis of lung cancer.
Interestingly men were more likely to present with ad-
vanced cancers, which could reflect health care seeking
behaviours but this pattern was not seen for colorectal
cancer. Alternatively it may reflect different smoking be-
haviour as male smokers consume more cigarettes per day
than women [22]. For both breast and prostate cancers,
practices in urban areas did less well than those in towns
and this may reflect the greater burden of primary care
work in such areas despite our attempts to adjust for pa-
tient level deprivation.
Hansen et al. [7] found that in Denmark, GP character-
istics such as perceived GP accessibility and opportunities
for referring were associated with patient and system
delay. This is similar to our findings that access to GP
(number of patients per GP and perceived ease of getting
an appointment) and use of TWW were associated with
reduced proportion of patients diagnosed at a more
advanced stage for breast and lung cancer. We found no
evidence of an association between being able to see a pre-
ferred GP and stage of cancer at diagnosis which differ
from findings by Rogers et al. [23] who showed a negative
association between seeing a preferred GP and cancer de-
tection rate. We found no evidence of an association be-
tween stage and total QOF points which reflects similar
findings by Levene et al. [24] with regards to specific QOF
indicators and cancer mortality. However this is different
to the findings of Bottle et al. [8] who found that higher
QOF protected against unplanned first-time admissions
for cancer. This may suggest that QOF score is important
in certain aspects of the patient journey. We found no evi-
dence that people registered at rural GP practices were
more likely to be diagnosed at a more advanced stage than
those living in urban areas. In relation to patient level dif-
ferences our findings are similar to other studies [25].
However our finding in relation to age and stage of breast
cancer are slightly unusual but this may be the result of
including cases diagnosed clinically with those diagnosed
by screening.
We have analysed data from a large proportion of four
of the most common cancers diagnosed in 2012. Linking
this to routinely collected data allowed us to analyse a
wide range of characteristics of primary care. Due to the
large number of exposure variables we conducted multiple
testing however where the p-value is very small chance
findings remain unlikely. It is worth noting where risk dif-
ferences are very small that even though statistically signifi-
cant this may be due to the large sample size. We have
focused on primary care as an important aspect in diagnos-
tic delay but there were some aspects we could not include,
for example general practitioner related factors such as
communication skills and trust, differences between general
practitioners within GP and number of consultations at
GPs [6, 23, 26, 27]. We also could not account for many
patient factors (psychosocial factors, emotional response,
support, co-morbidities or individual hospital use) or sec-
ondary care factors (different oncology services and radio-
logical investigations) [9, 28–30]. TWW referral rate may
be influenced by primary and secondary care aseven though
primary care makes the referrals if these are not seen within
2 weeks they do not count as TWW. Further limitations in-
clude the high percentage of missing ethnicity data which
meant we were unable to include this in the multivariable
models. We could not distinguish women with breast can-
cer diagnosed by screening rather than symptomatic pres-
entation as these data were incomplete within the NCRS.
This could alter the implications of the findings if there was
a correlation between exposure variables and screening de-
tection rates at practices. In addition there is little variation
in the number of days primary care delay for breast cancer
[31] once patients have presented. However characteristics
of primary care could still influence whether patients delay
in seeking care in the first place. We could also not distin-
guish people with colorectal cancer diagnosed by screening
rather than symptomatic presentation. This could be im-
portant if organizational or patient level factors influencing
the effectiveness of the screening programme are them-
selves correlated with GP level factors, which may or may
not be true.
More advanced stage was used as a proxy marker for a
poor outcome since more advanced stage is related to lower
survival. By diagnosing someone earlier (stage 3 to stage 2
or stage 4 to stage 3 for lung cancer) one year relative sur-
vival improves; female breast cancer 91 % to 98 %, prostate
cancer 99 % to 100 %, colorectal cancer 87 % to 91 % and
lung cancer 15 % to 36 % [32]. Given the large number of
people diagnosed with breast, colorectal, lung and prostate
cancer even small risk differences have the potential to make
large differences to survival. Improving access to primary
care and use of TWW may reduce more advanced stage at
diagnosis for breast and lung cancer, and therefore improve
survival. Use of investigations for gastrointestinal symptoms
could be important to reduce more advanced stage at diag-
nosis, though one must also consider the impact of inappro-
priate investigations and the cost of these procedures.
Conclusion
We have shown that higher use of TWWmay reduce more
advanced stage at diagnosis. The varied use and impact of
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TWW referral rate, conversion rate and detection rate
along with controversy relating to the TWW criteria high-
light this as a potential area for further research [33, 34]. In
addition further research is required to understand how
and in what circumstances TWW is most effective and
cost-effective, integrating risk assessment tools into this
policy [35]. Our results suggest that improving access to
primary care, efficient use of the referral systems and faster
investigations may reduce more advanced stage diagnosis
for female breast cancer, colorectal cancer and lung cancer.
However which apects of these areas and the exact way that
they may reduce advanced stage at diagnosis requires fur-
ther understanding. There were differences between the
four main cancers which suggest different policies may be
required for individual cancers to improve outcomes.
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